Parexel unveils new integrated FPS model to boost clinical research
Category: #health  By Mateen Dalal  Date: 2019-06-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

Parexel unveils new integrated FPS model to boost clinical research

Parexel stands as a pioneer in the delivery and development of a wide range of FSP, with full and flexible clinical development services

Parexel, a leading global provider of biopharmaceutical services and innovative therapies, recently announced that it has launched an enhanced integrated delivery model aimed at Functional Service Provider (FSP) services, in San Diego at the DIA 2019 Global Annual Meeting.

Reportedly, Parexel FSP reflects the strategic focus the company has towards offering solutions that are patient-focused and are tailored according to biopharma customers’ changing needs, ranging from full service to a functional and a hybrid approach.

Resources and multifunctional expertise are accessible to the customers through a single point of contact, while simultaneously maintaining business productivity and continuity to reduce complexity, drive efficiency and accelerate time to market, sources familiar with the matter informed.

Parexel’s Executive Vice President and Chief Commercial & Strategy Officer, Peyton Howell said that biopharma companies need hybrid and flexible approaches to their needs of outsourcing, owing to related blended models with functional services that represent a major proportion of the total clinical development.

Parexel supposedly has a proven track record in delivering and connecting targeted needs with an enhanced expertise in functional services and capability to integrate with the teams of their customers.

Apparently, Parexel stands as a pioneer in the delivery and development of a wide range of FSP, with full and flexible clinical development services and has delivered over 1,400 projects.

Parexel is able to leverage the company’s TMAC and ExecuPharm subsidiaries and the company’s broader FSP offers to provide hybrid capability and comprehensive FSP which stands unparalleled in the industry, Howell noted. For instance, ExecuPharm subsidiary provides qualified professionals to customers across functional areas that include study management and clinical monitoring.

For the record, biopharma customers have recognized Parexel and its ExecuPharm subsidiary for their FSP services. Moreover, ExecuPharm subsidiary has won multiple accolades for innovation and excellence over the past several years with Parexel being recognized for its FSP with an innovation award.

 

Source Credit- https://www.parexel.com/news-events-resources/news/current/parexel-launches-enhanced-integrated-functional-service-provider-model-drive-delivery-innovative-clinical-research-partnerships

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Novo Nordisk and Medtronic team up to offer digital diabetes solutions
Novo Nordisk and Medtronic team up to offer digital diabetes solutions
By Mateen Dalal

With growing population of diabetic patients, diabetes management is becoming a daunting activity. Sugar level management and insulin injections tracking is a difficult work. Thus, leading pharmaceutical companies are collaborating with medical devic...

Akesis unveils its advanced Galaxy™ RTi and Gemini360 at ASTRO 2019
Akesis unveils its advanced Galaxy™ RTi and Gemini360 at ASTRO 2019
By Mateen Dalal

The healthcare company will showcase its drugs in the ASTRO annual meeting 2019 that could help offer improved efficiency and confidence in treatment delivery. Akesis, Inc., a hospital and healthcare company based in the U.S. that offers innovative...

Adverum reveals positive results from Phase 1 trial of ADVM-022
Adverum reveals positive results from Phase 1 trial of ADVM-022
By Mateen Dalal

The drug was well tolerated and was safe, and has shown the capacity to improve the treatment paradigm for patients with wet AMD. Adverum Biotechnologies, Inc., a company that develops medical therapies for ocular and rare diseases, recently announc...